Arcellx Management

Management Kriterienprüfungen 2/4

Arcellx's CEO ist Rami Elghandour, ernannt in Jan 2021, hat eine Amtszeit von 3.33 Jahren. Die jährliche Gesamtvergütung beträgt $24.96M, bestehend aus 2.4% Gehalt und 97.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.17% der Aktien des Unternehmens, im Wert von $4.79M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Rami Elghandour

Geschäftsführender

US$25.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	2.4%
Amtszeit als Geschäftsführer	3.4yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Rami Elghandour im Vergleich zu den Einnahmen von Arcellx verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$25m	US$601k	-US$71m
Sep 30 2023	n/a	n/a	-US$130m
Jun 30 2023	n/a	n/a	-US$183m
Mar 31 2023	n/a	n/a	-US$190m
Dec 31 2022	US$14m	US$565k	-US$189m
Sep 30 2022	n/a	n/a	-US$170m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$23m	US$470k	-US$65m

Vergütung im Vergleich zum Markt: RamiDie Gesamtvergütung ($USD24.96M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.70M).

Entschädigung vs. Einkommen: RamiDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Rami Elghandour (45 yo)

3.4yrs

Amtszeit

US$24,964,306

Vergütung

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Rami Elghandour	Chairman of the Board	3.4yrs	US$24.96m	0.17% $ 5.0m
Michelle Gilson	Chief Financial Officer	2.1yrs	US$3.55m	0.037% $ 1.1m
Christopher Heery	Chief Medical Officer	3.2yrs	US$3.86m	0.017% $ 486.4k
Narinderjeet Singh	Chief Technical Officer	2.7yrs	keine Daten	keine Daten
David Tice	Chief Scientific Officer	2.9yrs	keine Daten	keine Daten
Myesha Lacy	Chief Investor & Communications Officer	3.4yrs	keine Daten	keine Daten
Maryam Abdul-Kareem	General Counsel & Chief Legal Officer	2yrs	keine Daten	keine Daten
Kate Aiken	Chief People Officer	3.4yrs	keine Daten	keine Daten
Neeraj Teotia	Chief Commercial Officer	3.2yrs	US$2.00m	keine Daten
Aileen Fernandes	Chief Business Officer	2yrs	keine Daten	keine Daten

3.0yrs

Durchschnittliche Betriebszugehörigkeit

47yo

Durchschnittliches Alter

Erfahrenes Management: ACLXDas Führungsteam des Unternehmens gilt als erfahren (3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Rami Elghandour	Chairman of the Board	3.4yrs	US$24.96m	0.17% $ 5.0m
David Lubner	Independent Director	3.8yrs	US$359.67k	0.040% $ 1.2m
Ali Behbahani	Independent Director	9.4yrs	US$355.17k	0.00079% $ 23.0k
Jill Carroll	Independent Director	6.8yrs	US$353.67k	keine Daten
Derek Yoon	Independent Director	4.2yrs	US$347.17k	keine Daten
Olivia Ware	Independent Director	2.1yrs	US$343.67k	0% $ 0
Kavita Patel	Independent Director	2.5yrs	US$344.67k	0% $ 0

3.8yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrener Vorstand: ACLXDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).

Arcellx Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Chairman of the Board recently sold US$2.4m worth of stock

Recent updates

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors

Arcellx: The Best Is Yet To Come

Arcellx, Inc. announced delayed 10-Q filing

Arcellx GAAP EPS of -$0.88

Arcellx down 9% on day lock-up period ends

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx, Inc. Announces New Positive Clinical Data from the Ongoing Phase 1 Expansion Study of Its Novel, Autologous, CART-ddBCMA Therapy

High number of new directors

Arcellx, Inc. Appoints Michelle Gilson as Chief Financial Officer

Arcellx, Inc. Announces Resignation of Lewis T. Williams from Board of Directors

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

High number of new directors

Arcellx, Inc. Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002 at the American Association for Cancer Research Annual Meeting 2022

High number of new directors